Skip to main content


Details of the Drug
Generic Name:
Drug Type:
Biosimilar growth factor
How the Drug is Given:

Subcutaneous (SC) injection or intravenously (IV)


Indications and Usage

Filgrastim-sndz is FDA approved as a biosimilar to US-licensed Neupogen® for the five indications for which Neupogen is approved:

  • Patients with cancer receiving myelosuppressive chemotherapy;
  • Patients with acute myeloid leukemia receiving induction or consolidation chemotherapy;
  • Patients with cancer undergoing bone marrow transplantation;
  • Patients undergoing autologous peripheral blood progenitor cell collection and therapy; and
  • Patients with severe chronic neutropenia.

Side effects needing medical attention

The most common side effects are: aching in the bones or muscles and redness, swelling or itching at injection site.

Serious side effects may include spleen rupture; serious allergic reactions that may cause rash, shortness of breath, wheezing and/or swelling around the mouth and eyes; fast pulse and sweating; and acute respiratory distress syndrome, a lung disease that can cause shortness of breath, difficulty breathing or increase the rate of breathing.

For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.